Drug Search Results
More Filters [+]

TS-161

Alternative Names: ts-161, ts161, ts 161
Latest Update: 2023-10-01
Latest Update Note: PubMed Publication

Product Description

TP0473292 (the active ingredient of TS-161) is a prodrug of a novel metabotropic glutamate (mGlu) 2/3 receptor antagonist being developed for the treatment of patients with depression.

Mechanisms of Action: MGLUR2/3 Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Taisho R&D
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TS-161

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Depressive Disorder, Major|Depressive Disorder, Treatment-Resistant

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

000101-M

P2

Recruiting

Depressive Disorder, Treatment-Resistant|Depressive Disorder, Major

2024-06-03

Recent News Events